IAN E KROP

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. KROP I, Kim S, Martín A, LoRusso P, Ferrero J, Badovinac Črnjević T, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18:743-754 pubmed publisher
    ..F Hoffman-La Roche/Genentech. ..
  2. KROP I, Beeram M, Modi S, Jones S, Holden S, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:2698-704 pubmed publisher
    ..6 mg/kg every 3 weeks, T-DM1 was associated with mild, reversible toxicity and substantial clinical activity in a heavily pretreated population. Phase II and III trials in patients with advanced HER2-positive breast cancer are under way. ..

Locale

Collaborators

Detail Information

Publications2

  1. KROP I, Kim S, Martín A, LoRusso P, Ferrero J, Badovinac Črnjević T, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18:743-754 pubmed publisher
    ..F Hoffman-La Roche/Genentech. ..
  2. KROP I, Beeram M, Modi S, Jones S, Holden S, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:2698-704 pubmed publisher
    ..6 mg/kg every 3 weeks, T-DM1 was associated with mild, reversible toxicity and substantial clinical activity in a heavily pretreated population. Phase II and III trials in patients with advanced HER2-positive breast cancer are under way. ..